Dennis W Raisch1, John A Rafi1, Cheng Chen1, Charles L Bennett2. 1. a College of Pharmacy , University of New Mexico , Albuquerque , NM , USA. 2. b College of Pharmacy , Medical University of South Carolina , Charleston , SC , USA.
Abstract
OBJECTIVE: To identify and summarize FDA's Adverse Event Reporting System (FAERS) cases of progressive multifocal leukoencephalopathy (PML) associated with biological and targeted cancer therapies (BTCT) that were approved between 2009 and 2015. METHODS: FAERS was searched using each BTCT name as primary or secondary suspect drug and the adverse reaction of PML. Among BTCTs with >2 case reports of PML, proportional reporting ratios (PRR) and 95% confidence intervals (CI) were calculated. RESULTS: Among 49 new BTCTs, 82 cases of PML were found for 16 drugs. Significant PRR signals were found among 7 (14.6%) BTCTs including: brentuximab (24.5, CI:14.8-40.6), ofatumumab (16.3, CI:9.6-27.4), alemtuzumab (9.9, CI:6.0-16.4), obinutuzumab (7.4, CI:2.4-22.8), ibrutinib (5.6 CI:3.0-10.5), belimumab (4.5 CI:2.3-9.0), and idelalisib (4.1, CI:1.3-12.6). Among the 82 cases with significant signals, confirmation of the diagnosis of PML using objective criteria was found in 56% of the cases. A limitation of FAERS data is that missing data are common. CONCLUSIONS: When using BTCTs, clinicians and patients consider the risk of PML versus the therapeutic benefit, particularly when used in combination with other drugs which may cause PML, such as rituximab. It is important to recognize that PML may occur in some conditions, such as chronic lymphocytic leukemia, regardless of drug therapy.
OBJECTIVE: To identify and summarize FDA's Adverse Event Reporting System (FAERS) cases of progressive multifocal leukoencephalopathy (PML) associated with biological and targeted cancer therapies (BTCT) that were approved between 2009 and 2015. METHODS: FAERS was searched using each BTCT name as primary or secondary suspect drug and the adverse reaction of PML. Among BTCTs with >2 case reports of PML, proportional reporting ratios (PRR) and 95% confidence intervals (CI) were calculated. RESULTS: Among 49 new BTCTs, 82 cases of PML were found for 16 drugs. Significant PRR signals were found among 7 (14.6%) BTCTs including: brentuximab (24.5, CI:14.8-40.6), ofatumumab (16.3, CI:9.6-27.4), alemtuzumab (9.9, CI:6.0-16.4), obinutuzumab (7.4, CI:2.4-22.8), ibrutinib (5.6 CI:3.0-10.5), belimumab (4.5 CI:2.3-9.0), and idelalisib (4.1, CI:1.3-12.6). Among the 82 cases with significant signals, confirmation of the diagnosis of PML using objective criteria was found in 56% of the cases. A limitation of FAERS data is that missing data are common. CONCLUSIONS: When using BTCTs, clinicians and patients consider the risk of PML versus the therapeutic benefit, particularly when used in combination with other drugs which may cause PML, such as rituximab. It is important to recognize that PML may occur in some conditions, such as chronic lymphocytic leukemia, regardless of drug therapy.
Entities:
Keywords:
FDA’s adverse event reporting system; Progressive multifocal leukoencephalopathy; biological drugs; data mining signal detection; targeted cancer therapies
Authors: N S Vermeer; S M J M Straus; A K Mantel-Teeuwisse; A Hidalgo-Simon; A C G Egberts; H G M Leufkens; M L De Bruin Journal: Clin Pharmacol Ther Date: 2015-09-08 Impact factor: 6.875
Authors: David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath Journal: Lancet Neurol Date: 2010-04 Impact factor: 44.182
Authors: Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett Journal: Cancer Date: 2014-04-25 Impact factor: 6.860
Authors: Monica E Mazda; Jared R Brosch; Andrea L Wiens; José M Bonnin; Aaron P Kamer; David H Mattson; Riley J Snook Journal: Int J Neurosci Date: 2013-02-06 Impact factor: 2.292
Authors: C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young Journal: J Neurol Neurosurg Psychiatry Date: 2015-10-22 Impact factor: 10.154
Authors: Jacopo Olivieri; Pietro Lauzzana; Stefano Volpetti; Marco Girgenti; Giuseppe Petruzzellis; Anna Candoni; Renato Fanin Journal: Hemasphere Date: 2022-05-31
Authors: Rachel A Sabol; Virginia Noxon; Oliver Sartor; Joseph R Berger; Zaina Qureshi; Dennis W Raisch; LeAnn B Norris; Paul R Yarnold; Peter Georgantopoulos; William J Hrushesky; Laura Bobolts; Paul Ray; Akida Lebby; Robert C Kane; Charles L Bennett Journal: Cancer Med Date: 2017-06-20 Impact factor: 4.452
Authors: Simona Malucchi; Marco Capobianco; Marianna Lo Re; Maria Malentacchi; Alessia di Sapio; Manuela Matta; Francesca Sperli; Antonio Bertolotto Journal: Neurol Ther Date: 2016-12-03